As I found the registry entry for the trial I have amended the thread title to match the trial. Interestingly, it seems that one of the exclusion criteria is having ME.
Study hypothesis
An activity tracking and personalised just-in-time adaptive intervention (JITAI) will reduce symptoms of post-exertional malaise (PEM) in people with long-COVID compared to usual care six months after ransdomisation.
Ethics approval
Approved 12/08/2021, University of the West of Scotland Health and Life Sciences Ethics Committee (Stephenson Place Hamilton International Technology Park Blantyre, Glasgow G72 0LH; no telephone contact provided ;
gary.boyd@uws.ac.uk), ref:16638
Study design
Pragmatic single centre randomized controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Home
Trial type
Quality of life
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet.
Condition
Reducing frequency and severity of post-exertional malaise in people with long COVID.
Intervention
250 participants with long COVID will be randomised into intervention and control groups using a secure, independent online trial allocation service. Allocation will be stratified for age and sex.
125 Participants in the control group will receive standard advice on pacing and managing energy levels. Participants in the intervention group will receive an activity tracker and a bespoke mobile phone 'App'. Each day, using their activity tracking data intervention participants will receive individualised alert messages when they spend time above a specific HR determined activity threshold (eg. time above 130 bpm) and if they have not spent sufficient time at rest.
Intervention type
Behavioural
Phase
Drug names
Primary outcome measure
Post-exertional malaise using the PEM questionnaire at baseline and at 6 months.
Secondary outcome measures
1. PEM trend using PEM questionnaire assessed monthly
2. Depression trend using PHQ-9 monthy
3. Depression change using PHq-9 assessed at baseline and 6 months.
4. Fatigue trend using FSS monthly
5. Fatigue change using FSS at baseline and 6 months.
6. Quality of life trend using SF36 monthly
7. Quality of life change using SF36 at baseline and 6 months
8. Self-efficacy trend using Self Efficacy Scale monthly
9. Cognitive function using a variation of the symbol digit modalities test monthly
10. Cognitive function using a variation of the symbol digit modalities test at baseline and 6 months.
11. Pain using Pain VAS assessed at baseline and 6 months
12. Pain trend using Pain VAS assessed monthly between months 0-6
13. Resting heart rate assessed daily using the activity tracker
Overall trial start date
16/07/2021
Overall trial end date
31/12/2022
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Adults reporting persistent symptoms which have lasted for at least 8-weeks after initial infection with COVID-19 and which interfere with day-to-day activity.
2. Participants should be recovering at home and have access to an Android (SDK16 or higher) or iPhone (iOS version 10 or higher) mobile phone.
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Planned sample size is 172 with 86 participants per group. To allow for 30% attrition, we plan to recruit a total of 125 per group and 250 participants in total.
Participant exclusion criteria
1. Currently receiving ongoing care for LC via primary or secondary care services.
2. Prior diagnosis with a comorbidity with similar symptoms (e.g. ME/CFS).
3. Currently receiving a therapy known to cause exacerbations.
4. Currently participating in another LC focussed intervention.
5. Impaired cognitive function which compromises comprehension of study information or messaging.
6. Insufficient English language for messaging to be effective.
7. No mobile phone access
Recruitment start date
01/12/2021
Recruitment end date
01/05/2022
More at
https://www.isrctn.com/ISRCTN16033549